Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 10;14:746. doi: 10.1038/s41467-023-36334-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Correlation between IL11 and aFib-RS in n = 177 CRC tumors from GSE17536. Correlation (R) and Spearman p value are indicated. b Relative expression levels of IL11 in CCD-18Co treated with increasing concentration of oxaliplatin. n = 3 biologically independent experiments. Values are mean ± sd. p values are indicated. c Relative expression levels of IL11 in CAF1 and CAF2 treated with oxaliplatin. n = 3 biologically independent experiments. Values are mean ± sd. p values are indicated. d Relative expression levels of IL11 in CCD-18Co 6, 12, 90 and 180 days after oxaliplatin retrieval. n = 3 biologically independent experiments. Values are mean ± sd. p values are indicated. e Relative expression levels of IL11 in CCD-18Co treated with oxaliplatin w/o TGF-beta pathway inhibitor (TBRi). n = 3 biologically independent experiments. Values are mean ± sd. p values are indicated. f Kaplan–Meier curve displays DFS for GSE39582 patients presenting low (blue; n = 136) or high (red; n = 383) expression levels of IL11. HR, CI and p value are indicated. g IL11 levels in n = 1029 CRC patients classified by CMS subtypes (CMS1 n = 175; CMS2 n = 445; CMS3 n = 147, CMS4 n = 262). Central mark indicates the median, box extends from the 25th to 75th percentiles, whiskers represent the maximum and minimum data point. p values are indicated. h Kaplan–Meier curve displays DFS for GSE39582_CMS4 patients presenting low (blue; n = 26) or high (red; n = 95) expression levels of IL11. HR, CI and p value are indicated. i GSEA of CRC-IL11RS comparing relapsing (n = 13) to non-relapsing (n = 38) patients after CT in GSE14333. j Kaplan–Meier plot displays tumor initiation overtime in nude mice injected subcutaneously with 30,000 HT29-M6 control (blue; n = 10) or IL11-secreting cells (red; n = 10). p value is indicated. k Kaplan–Meier plot displays tumor initiation overtime in nude mice injected subcutaneously with 30,000 HT29-M6 control cells (dashed red; n = 12), TGF-beta secreting cells (red; n = 12), shIL11RA cells (dashed blue; n = 8) or with shIL11RA/TGF-beta-secreting cells (blue; n = 8). p value is indicated. CRC: HT29-M6; TFS tumor-free survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, Ox oxaliplatin, Ct control, CT chemotherapy. Two-sided, unpaired t-test p values (p) are indicated for b–e, g. Log-rank (Mantel–Cox test) p values (p) are indicated for f, h, j, k. GSEA nominal p value (p) and FDR-adjusted p value are indicated for i. Source data are provided as a Source Data file.